Focused ultrasound-induced blood–brain barrier disruption enhances the delivery of cytarabine to the rat brain

References

• Lamba JK. Pharmacogenomics of cytarabine in childhood leukemia. Pharmacogenomics. 2011;12(12):1629–32.
   PubMed Web of Science ®Google Scholar
• Tallman MS. Therapy of acute myeloid leukemia. Cancer Control. 2001;8(1):62–78.
   PubMedGoogle Scholar
• Barredo J, Ritchey AK. Controversies in the management of central nervous system leukemia. Pediatr Hematol Oncol. 2010;27(5):329–32.
   PubMed Web of Science ®Google Scholar
• Simone JV. History of the treatment of childhood ALL: a paradigm for cancer cure. Best Pract Res Clin Haematol. 2006;19(2):353–9.
   PubMed Web of Science ®Google Scholar
• Riccardi R, Riccardi A, Lasorella A, Servidei T, Mastrangelo S. Cranial irradiation and permeability of blood-brain barrier to cytosine arabinoside in children with acute leukemia. Clin Cancer Res. 1998;4(1):69–73.
   PubMed Web of Science ®Google Scholar
• Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al.. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355(15):1572–82.
   PubMed Web of Science ®Google Scholar
• Geenen MM, Cardous-Ubbink MC, Kremer LC, van den Bos C, van der Pal HJ, Heinen RC, et al.. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA. 2007;297(24):2705–15.
   PubMed Web of Science ®Google Scholar
• Waber DP, Turek J, Catania L, Stevenson K, Robaey P, Romero I, et al.. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. J Clin Oncol. 2007;25(31):4914–21.
   PubMed Web of Science ®Google Scholar
• Johnston SR. The role of chemotherapy and targeted agents in patients with metastatic breast cancer. Eur J Cancer. 2011;47 Suppl 3: S38–47.
   PubMed Web of Science ®Google Scholar
• Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, et al.. Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer. 2011;11:only 205.
   Google Scholar
• Lainakis G, Zagouri F, Kastritis E, Sergentanis TN, Bozas G, Dimopoulos MA, et al.. Systemic chemotherapy with pemetrexed and cisplatin for malignant peritoneal mesothelioma: a single institution experience. Tumori. 2011;97(1):25–9.
   PubMed Web of Science ®Google Scholar
• Siegal T, Zylber-Katz E. Strategies for increasing drug delivery to the brain: focus on brain lymphoma. Clin Pharmacokinet. 2002;41(3):171–86.
   PubMed Web of Science ®Google Scholar
• Blakeley J. Drug delivery to brain tumors. Curr Neurol Neurosci Rep. 2008;8(3):235–41.
   PubMed Web of Science ®Google Scholar
• Konofagou EE, Tung YS, Choi J, Deffieux T, Baseri B, Vlachos F. Ultrasound-Induced Blood-Brain Barrier Opening. Curr Pharm Biotechnol. 2012;13(7):1332–45.
   PubMed Web of Science ®Google Scholar
• Huang Q, Deng J, Wang F, Chen S, Liu Y, Wang Z, et al.. Targeted gene delivery to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Exp Neurol. 2012;233(1):350–6.
   PubMed Web of Science ®Google Scholar
• Ting CY, Fan CH, Liu HL, Huang CY, Hsieh HY, Yen TC, et al.. Concurrent blood-brain barrier opening and local drug delivery using drug-carrying microbubbles and focused ultrasound for brain glioma treatment. Biomaterials. 2012;33(2):704–12.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun. 2006;340(4):1085–90.
   PubMed Web of Science ®Google Scholar
• Mei J, Cheng Y, Song Y, Yang Y, Wang F, Liu Y, et al.. Experimental study on targeted methotrexate delivery to the rabbit brain via magnetic resonance imaging-guided focused ultrasound. J Ultrasound Med. 2009;28(7):871–80.
   PubMed Web of Science ®Google Scholar
• Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol. 2010;6(1):117–125.
   PubMed Web of Science ®Google Scholar
• Ferguson S, Lesniak MS. Convection enhanced drug delivery of novel therapeutic agents to malignant brain tumors. Curr Drug Deliv. 2007;4(2):169–80.
   PubMedGoogle Scholar
• Deng CX. Targeted drug delivery across the blood-brain barrier using ultrasound technique. Ther Deliv. 2010;1(6):819–48.
   PubMedGoogle Scholar
• Hynynen K, McDannold N, Martin H, Jolesz FA, Vykhodtseva N. The threshold for brain damage in rabbits induced by bursts of ultrasound in the presence of an ultrasound contrast agent (Optison). Ultrasound Med Biol. 2003;29(3):473–81.
   PubMed Web of Science ®Google Scholar
• Abbott NJ. Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol. 2000;20(2):131–47.
   PubMed Web of Science ®Google Scholar
• Lawrie A, Brisken AF, Francis SE, Tayler DI, Chamberlain J, Crossman DC, et al.. Ultrasound enhances reporter gene expression after transfection of vascular cells in vitro. Circulation. 1999;99(20):2617–20.
   PubMed Web of Science ®Google Scholar
• Dijkmans PA, Juffermans LJ, Musters RJ, van Wamel A, ten Cate FJ, van Gilst W, et al.. Microbubbles and ultrasound: from diagnosis to therapy. Eur J Echocardiogr. 2004;5(4):245–56.
   PubMedGoogle Scholar
• Yu T, Hu D, Xu C. Microbubbles improve the ablation efficiency of extracorporeal high intensity focused ultrasound against kidney tissues. World J Urol. 2008;26(6):631–36.
   PubMed Web of Science ®Google Scholar
• Deng J, Huang Q, Wang F, Liu Y, Wang Z, Wang Z, et al.. The role of caveolin-1 in blood–brain barrier disruption induced by focused ultrasound combined with microbubbles. J Mol Neurosci. 2012;46(3):677–87.
   PubMed Web of Science ®Google Scholar
• Samiotaki G, Vlachos F, Tung YS, Konofagou EE. A quantitative pressure and microbubble-size dependence study of focused ultrasound-induced blood-brain barrier opening reversibility in vivo using MRI. Magn Reson Med. 2012;67(3):769–77.
   PubMed Web of Science ®Google Scholar
• Sheikov N, McDannold N, Sharma S, Hynynen K. Effect of focused ultrasound applied with an ultrasound contrast agent on the tight junctional integrity of the brain microvascular endothelium. Ultrasound Med Biol. 2008;34(7):1093–104.
   PubMed Web of Science ®Google Scholar
• Liu HL, Yang HW, Hua MY, Wei KC. Enhanced therapeutic agent delivery through magnetic resonance imaging-monitored focused ultrasound blood–brain barrier disruption for brain tumor treatment: an overview of the current preclinical status. Neurosurg Focus. 2012;32(1):only E4.
   Google Scholar
• Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. 2007;121(4):901–7.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A. 2006;103(31):11719–23.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Thomas D, Cortes J, Kantarjian HM, O’Brien S. Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies. Cancer. 2010;116(10):2290–300.
   PubMed Web of Science ®Google Scholar
• Denora N, Laquintana V, Trapani A, Lopedota A, Latrofa A, Gallo JM, et al.. Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential. Mol Pharm. 2010;7(6):2255–69.
   PubMedGoogle Scholar
• Jabbour E, O’Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, et al.. Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;109(8):3214–8.
   PubMed Web of Science ®Google Scholar
• Gállego Pérez-Larraya J, Palma JA, Carmona-Iragui M, Fernández-Torrón R, Irimia P, Rodríguez-Otero P, et al.. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma. J Neurooncol. 2011;103(3):603–9.
   PubMed Web of Science ®Google Scholar